Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:BLCO NYSE:SNN NYSE:SOLV NYSE:ZBH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLCOBausch + Lomb$15.95+0.2%$16.15$10.99▼$18.92$5.69B0.59518,705 shs264,078 shsSNNSmith & Nephew SNATS$30.51-0.1%$31.91$28.33▼$38.79$13.03B0.571.35 million shs1.04 million shsSOLVSolventum$76.92+0.1%$68.68$62.38▼$88.20$13.32B0.591.61 million shs1.63 million shsZBHZimmer Biomet$85.41-0.1%$88.82$79.12▼$108.29$16.52B0.482.94 million shs1.81 million shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLCOBausch + Lomb0.00%-0.85%+0.71%-11.09%+41.32%SNNSmith & Nephew SNATS0.00%+3.22%-3.39%-15.66%+6.47%SOLVSolventum0.00%+3.59%+12.21%+6.07%+8.57%ZBHZimmer Biomet0.00%+2.01%-6.42%-14.06%-8.01%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLCOBausch + Lomb$15.95+0.2%$16.15$10.99▼$18.92$5.69B0.59518,705 shs264,078 shsSNNSmith & Nephew SNATS$30.51-0.1%$31.91$28.33▼$38.79$13.03B0.571.35 million shs1.04 million shsSOLVSolventum$76.92+0.1%$68.68$62.38▼$88.20$13.32B0.591.61 million shs1.63 million shsZBHZimmer Biomet$85.41-0.1%$88.82$79.12▼$108.29$16.52B0.482.94 million shs1.81 million shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLCOBausch + Lomb0.00%-0.85%+0.71%-11.09%+41.32%SNNSmith & Nephew SNATS0.00%+3.22%-3.39%-15.66%+6.47%SOLVSolventum0.00%+3.59%+12.21%+6.07%+8.57%ZBHZimmer Biomet0.00%+2.01%-6.42%-14.06%-8.01%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBLCOBausch + Lomb 2.21Hold$18.0813.37% UpsideSNNSmith & Nephew SNATS 2.50Moderate Buy$30.931.38% UpsideSOLVSolventum 2.50Moderate Buy$84.259.53% UpsideZBHZimmer Biomet 2.26Hold$102.8020.36% UpsideCurrent Analyst Ratings BreakdownLatest BLCO, ZBH, SOLV, and SNN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/25/2026SNNSmith & Nephew SNATS The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/15/2026SOLVSolventum WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$94.005/14/2026SOLVSolventum UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$50.005/11/2026SNNSmith & Nephew SNATS Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$31.855/11/2026SNNSmith & Nephew SNATS Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetHold$32.00 ➝ $30.005/6/2026SOLVSolventum UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$82.00 ➝ $78.005/6/2026SOLVSolventum Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$105.00 ➝ $90.005/6/2026SOLVSolventum KeyCorpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$92.00 ➝ $93.005/6/2026SOLVSolventum Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$83.00 ➝ $70.005/6/2026SOLVSolventum BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$89.004/30/2026BLCOBausch + Lomb Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$16.00(Data available from 5/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBLCOBausch + Lomb$5.10B1.12$1.67 per share9.54$18.09 per share0.88SNNSmith & Nephew SNATS$6.16B2.11$3.43 per share8.90$12.45 per share2.45SOLVSolventum$8.33B1.60$9.00 per share8.55$28.69 per share2.68ZBHZimmer Biomet$8.23B2.01$13.73 per share6.22$65.55 per share1.30Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBLCOBausch + Lomb-$360M-$0.62N/A14.770.49-4.21%3.60%1.69%7/29/2026 (Estimated)SNNSmith & Nephew SNATS$625MN/AN/A12.151.00N/AN/AN/A8/4/2026 (Estimated)SOLVSolventum$1.56B$8.169.4310.801.1917.33%23.51%7.63%8/6/2026 (Estimated)ZBHZimmer Biomet$705.20M$3.8522.199.521.989.05%13.24%7.28%8/6/2026 (Estimated)Latest BLCO, ZBH, SOLV, and SNN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/5/2026Q1 2026SOLVSolventum$1.35$1.48+$0.13$0.07$1.97 billion$2.01 billion4/29/2026Q1 2026BLCOBausch + Lomb$0.06$0.08+$0.02-$0.20$1.22 billion$1.24 billion4/28/2026Q1 2026ZBHZimmer Biomet$1.86$2.09+$0.23$1.22$2.07 billion$2.09 billion2/26/2026Q4 2025SOLVSolventum$1.50$1.57+$0.07$0.36$1.96 billion$2.00 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBLCOBausch + LombN/AN/AN/AN/AN/ASNNSmith & Nephew SNATS$0.933.05%N/AN/AN/ASOLVSolventumN/AN/AN/AN/AN/AZBHZimmer Biomet$0.961.12%N/A24.94%N/ALatest BLCO, ZBH, SOLV, and SNN DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/22/2026ZBHZimmer Biometquarterly$0.241.12%6/25/20266/25/20267/31/20263/5/2026SNNSmith & Nephew SNATS$0.48203.04%3/27/20263/27/20265/27/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBLCOBausch + Lomb0.781.530.99SNNSmith & Nephew SNATS0.602.571.25SOLVSolventum0.961.070.75ZBHZimmer Biomet0.501.730.95Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBLCOBausch + Lomb11.07%SNNSmith & Nephew SNATS25.64%SOLVSolventumN/AZBHZimmer Biomet88.89%Insider OwnershipCompanyInsider OwnershipBLCOBausch + Lomb1.45%SNNSmith & Nephew SNATS1.00%SOLVSolventum0.24%ZBHZimmer Biomet1.28%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBLCOBausch + Lomb13,000356.57 million351.40 millionOptionableSNNSmith & Nephew SNATS16,988426.99 million422.72 millionOptionableSOLVSolventum20,000173.18 million172.76 millionOptionableZBHZimmer Biomet17,000193.46 million190.99 millionOptionableBLCO, ZBH, SOLV, and SNN HeadlinesRecent News About These CompaniesMorningstar Investment Management LLC Acquires 40,610 Shares of Zimmer Biomet Holdings, Inc. $ZBHMay 25 at 6:26 AM | marketbeat.com5 Best Robotic Surgery Stocks to BuyMay 24 at 8:31 AM | insidermonkey.comPNC Financial Services Group Inc. Raises Position in Zimmer Biomet Holdings, Inc. $ZBHMay 24 at 5:06 AM | marketbeat.comZimmer Biomet gets expanded FDA nod for Rosa robotic shoulder systemMay 22 at 6:49 PM | massdevice.comZimmer Biomet Announces Quarterly Dividend for Second Quarter of 2026May 22 at 4:30 PM | prnewswire.comZimmer Biomet Holdings, Inc. $ZBH Stake Cut by Heritage Investors Management CorpMay 22 at 6:16 AM | marketbeat.comZimmer Biomet Holdings, Inc. (NYSE:ZBH) Receives Consensus Rating of "Hold" from AnalystsMay 20, 2026 | marketbeat.comGabelli Funds LLC Boosts Holdings in Zimmer Biomet Holdings, Inc. $ZBHMay 20, 2026 | marketbeat.comZimmer Biomet Holdings, Inc. $ZBH Shares Sold by Independent Advisor AllianceMay 19, 2026 | marketbeat.comHere's Why Zimmer Biomet (ZBH) is a Strong Value StockMay 18, 2026 | zacks.comABT vs. ZBH: Which Surgical Equipment Stock Is the Better Bet Now?May 18, 2026 | zacks.comEubel Brady & Suttman Asset Management Inc. Decreases Position in Zimmer Biomet Holdings, Inc. $ZBHMay 17, 2026 | marketbeat.comHills Bank & Trust Co Sells 14,826 Shares of Zimmer Biomet Holdings, Inc. $ZBHMay 17, 2026 | marketbeat.comWhat are Wall Street analysts' target price for Zimmer Biomet stock?May 15, 2026 | msn.comZimmer Biomet (ZBH) Valuation Check After Announcing Expanded US$1b Share Repurchase PlanMay 15, 2026 | finance.yahoo.comZimmer Biomet Holdings, Inc. $ZBH Shares Purchased by Thrivent Financial for LutheransMay 15, 2026 | marketbeat.comPacer Advisors Inc. Has $62.74 Million Holdings in Zimmer Biomet Holdings, Inc. $ZBHMay 14, 2026 | marketbeat.comZimmer Biomet increases planned share repurchase to up to $1B by end of 2026May 13, 2026 | massdevice.comZimmer Biomet Holdings, Inc. (ZBH) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 13, 2026 | seekingalpha.comWhy Zimmer Biomet (ZBH) stock is up todayMay 13, 2026 | msn.comZimmer Biomet Increases Share Repurchase Expectations -- Up to $1 Billion by Year EndMay 12, 2026 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 2026Apple Talks Just Changed Everything for IntelBy Sam Quirke | May 6, 20263 Energy Stocks to Buy and 2 to Avoid as AI Power Demand ExplodesBy Bridget Bennett | May 4, 2026Bloom Energy May Be Solving AI’s Biggest Power ProblemBy Thomas Hughes | May 1, 2026Target the Red-Hot Spin-Off and Merger Space With These ETFsBy Nathan Reiff | May 17, 2026BLCO, ZBH, SOLV, and SNN Company DescriptionsBausch + Lomb NYSE:BLCO$15.95 +0.03 (+0.19%) Closing price 05/22/2026 03:59 PM EasternExtended Trading$15.92 -0.03 (-0.19%) As of 05/22/2026 05:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. Its Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation is a subsidiary of Bausch Health Companies Inc.Smith & Nephew SNATS NYSE:SNN$30.50 -0.03 (-0.08%) Closing price 05/22/2026 03:59 PM EasternExtended Trading$30.54 +0.03 (+0.10%) As of 05/22/2026 07:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT. The Advanced Wound Management segment includes advanced wound care, advanced wound bioactives, and advanced wound devices businesses. The company was founded in 1856 and is headquartered in Watford, the United Kingdom.Solventum NYSE:SOLV$76.92 +0.09 (+0.12%) Closing price 05/22/2026 03:59 PM EasternExtended Trading$76.83 -0.09 (-0.12%) As of 05/22/2026 06:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes. The Dental Solutions segment provides a comprehensive suite of dental and orthodontic products including brackets, aligners, restorative cements, and bonding agents. The Health Information Systems provides software solutions including computer-assisted, physician documentation, direct-to-bill and coding automation, classification methodologies, speech, recognition, and data visualization platforms. The Purification and Filtration segment provides purification and filtration technologies including filters, purifiers, cartridges, and membranes. The company was incorporated in 2023 and is based in Saint Paul, Minnesota.Zimmer Biomet NYSE:ZBH$85.41 -0.09 (-0.10%) Closing price 05/22/2026 03:59 PM EasternExtended Trading$85.50 +0.09 (+0.11%) As of 05/22/2026 07:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers robotic, surgical, and bone cement products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/18 - 05/22 Ross Stores Earnings Beat Sends Stock To New Highs Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus? Workday Validates AI Flywheel: Stock Price Recovery Begins Apparel Earnings Winners and Losers: Ralph Lauren Takes Off SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? The Careful Consumer: What Q1 Earnings Reveal—And Where Cracks May Appear Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
